Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Enrolling by invitation Not applicable

Unique Electroencephalography (EEG) Markers of Habit Behaviors in Obsessive-Compulsive Disorder (OCD)

NCT06882902 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2024-05-05
Last updated
2025-05-28

Condition(s) studied

Obsessive-Compulsive Disorder

Investigational drug(s) / intervention(s)

habit formation training

habit formation training: Participants need to perform habit formation exercises for 4 consecutive days. During the exercises, participants will see a picture stimulus and need to learn the corresponding key press. Each day, participants will spend 30 minutes on the training.

Study summary

This study focuses on explaining the occurrence and development of compulsive behaviors from habit hypothesis. Investigators will study both OCD patients and healthy individuals using Hardwick's forced-response time task(2019), the habit Go/No-Go task, and the Intra-Extra Dimensional Set Shift task. Investigators aim to explore the cognitive abilities and differences between OCD patients and healthy controls in these three tasks. Control variables will include participants' levels of anxiety, depression, and stress, as well as sense of incompleteness and intolerance of uncertainty levels. By examining the differences in habit formation and expression abilities between OCD patients and healthy controls, and exploring the specific brain electroencephalographic activity processes in OCD patients, investigators hope to reveal the abnormal neural activity in habit-related circuits in OCD patients. This could provide new insights for the diagnosis and treatment of OCD.

Eligibility

Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Aged between 18 and 50; 2. Y-BOCS score greater than or equal to 16; 3. Meet DSM-5 diagnostic criteria with no medication changes in the past two weeks; 4. Right-handed. Exclusion Criteria: 1. Diagnosed with any DSM-5 disorder other than OCD; 2. Have a major physical illness; 3. Have strong suicidal ideation.

Primary outcome measure(s)

  • Reduction of Y-BOCS scores — baseline#after- intervention#1 weeks# (pre-intervention, after intervention, one weeks after intervention)
    We defined the habit training response as the percent reduction of Y-BOCS scores greater than or equal to 35%.

Trial sites (1)

FacilityCityRegionStatus
Shanghai Mental Health Center Shanghai Shanghai Municipality
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06882902 on ClinicalTrials.gov ↗ ← All trials in China